AnaptysBio Analyst Ratings
AnaptysBio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 16.51% | Wedbush | $18 → $20 | Maintains | Neutral |
| 11/02/2023 | 22.33% | UBS | $28 → $21 | Maintains | Neutral |
| 08/08/2023 | 51.46% | Wedbush | $29 → $26 | Maintains | Neutral |
| 05/22/2023 | 74.76% | JP Morgan | $31 → $30 | Upgrades | Underweight → Neutral |
| 05/12/2023 | 68.94% | Wedbush | → $29 | Reiterates | Neutral → Neutral |
| 05/12/2023 | 162.15% | Guggenheim | $44 → $45 | Maintains | Buy |
| 04/12/2023 | 80.59% | JP Morgan | $32 → $31 | Maintains | Underweight |
| 01/06/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/18/2022 | 86.42% | JP Morgan | $24 → $32 | Maintains | Underweight |
| 11/09/2022 | 121.37% | Raymond James | $30 → $38 | Maintains | Outperform |
| 11/01/2022 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 09/19/2022 | 103.89% | HC Wainwright & Co. | → $35 | Assumes | → Buy |
| 09/13/2022 | 63.11% | Truist Securities | $50 → $28 | Downgrades | Buy → Hold |
| 09/01/2022 | 103.89% | Raymond James | → $35 | Initiates Coverage On | → Outperform |
| 03/22/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 03/08/2022 | 167.97% | HC Wainwright & Co. | $43 → $46 | Maintains | Buy |
| 06/22/2021 | 150.5% | HC Wainwright & Co. | → $43 | Initiates Coverage On | → Buy |
| 05/21/2021 | 68.94% | UBS | → $29 | Initiates Coverage On | → Neutral |
| 03/16/2021 | 98.07% | Truist Securities | $27 → $34 | Upgrades | Hold → Buy |
| 03/09/2021 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 02/11/2021 | 133.02% | JP Morgan | $19 → $40 | Upgrades | Underweight → Overweight |
| 10/27/2020 | 103.89% | Wedbush | $20 → $35 | Upgrades | Neutral → Outperform |
| 10/14/2020 | 109.72% | Guggenheim | → $36 | Upgrades | Neutral → Buy |
| 05/07/2020 | -6.79% | Credit Suisse | $14 → $16 | Maintains | Neutral |
| 03/03/2020 | -18.44% | SunTrust Robinson Humphrey | $15 → $14 | Maintains | Hold |
| 11/08/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 10/03/2019 | 179.62% | Credit Suisse | $75 → $48 | Maintains | Neutral |
| 08/09/2019 | 336.91% | Credit Suisse | $79 → $75 | Maintains | Neutral |
| 06/24/2019 | 441.77% | SunTrust Robinson Humphrey | $125 → $93 | Maintains | Buy |
| 06/21/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
| 02/22/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 12/20/2018 | 634.01% | HC Wainwright & Co. | → $126 | Initiates Coverage On | → Buy |
| 11/21/2018 | 569.93% | JP Morgan | → $115 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/03/2023 | 16.51% | Wedbush | 18 美元 → 20 美元 | 維護 | 中立 |
| 11/02/2023 | 22.33% | 瑞銀（UBS） | 28 美元 → 21 美元 | 維護 | 中立 |
| 08/08/2023 | 51.46% | Wedbush | 29 美元 → 26 美元 | 維護 | 中立 |
| 05/22/2023 | 74.76% | 摩根大通 | 31 美元 → 30 美元 | 升級 | 體重不足 → 中性 |
| 05/12/2023 | 68.94% | Wedbush | → 29 美元 | 重申 | 中立 → 中立 |
| 05/12/2023 | 162.15% | 古根海姆 | 44 美元 → 45 美元 | 維護 | 購買 |
| 2023 年 12 月 4 日 | 80.59% | 摩根大通 | 32 美元 → 31 美元 | 維護 | 體重不足 |
| 01/06/2023 | — | 雷蒙德·詹姆 | 降級 | 跑贏大盤 → 市場表現 | |
| 11/18/2022 | 86.42% | 摩根大通 | 24 美元 → 32 美元 | 維護 | 體重不足 |
| 11/09/2022 | 121.37% | 雷蒙德·詹姆 | 30 美元 → 38 美元 | 維護 | 跑贏大盤 |
| 11/01/2022 | — | 古根海姆 | 升級 | 中性 → 買入 | |
| 09/19/2022 | 103.89% | HC Wainwright & Co. | → 35 美元 | 假設 | → 購買 |
| 09/13/2022 | 63.11% | Truist 證券 | 50 美元 → 28 美元 | 降級 | 買入 → 持有 |
| 09/01/2022 | 103.89% | 雷蒙德·詹姆 | → 35 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 03/22/2022 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 03/08/2022 | 167.97% | HC Wainwright & Co. | 43 美元 → 46 美元 | 維護 | 購買 |
| 06/22/2021 | 150.5% | HC Wainwright & Co. | → 43 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/21/2021 | 68.94% | 瑞銀（UBS） | → 29 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 03/16/2021 | 98.07% | Truist 證券 | 27 美元 → 34 美元 | 升級 | 持有 → 買入 |
| 2021 年 9 月 3 日 | — | Wedbush | 降級 | 跑贏大盤 → 中立 | |
| 02/11/2021 | 133.02% | 摩根大通 | 19 美元 → 40 美元 | 升級 | 體重過輕 → 超重 |
| 10/27/2020 | 103.89% | Wedbush | 20 美元 → 35 美元 | 升級 | 中性 → 跑贏大盤 |
| 2020 年 10 月 14 日 | 109.72% | 古根海姆 | → 36 美元 | 升級 | 中性 → 買入 |
| 05/07/2020 | -6.79% | 瑞士信貸 | 14 美元 → 16 美元 | 維護 | 中立 |
| 2020 年 3 月 3 日 | -18.44% | SunTrust 羅賓遜·漢弗萊 | 15 美元 → 14 美元 | 維護 | 保持 |
| 11/08/2019 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 10/03/2019 | 179.62% | 瑞士信貸 | 75 美元 → 48 美元 | 維護 | 中立 |
| 08/09/2019 | 336.91% | 瑞士信貸 | 79 美元 → 75 美元 | 維護 | 中立 |
| 06/24/2019 | 441.77% | SunTrust 羅賓遜·漢弗萊 | 125 美元 → 93 美元 | 維護 | 購買 |
| 06/21/2019 | — | 瑞士信貸 | 降級 | 跑贏大盤 → 中立 | |
| 02/22/2019 | — | 古根海姆 | 啓動覆蓋範圍開啓 | → 購買 | |
| 2018 年 12 月 20 日 | 634.01% | HC Wainwright & Co. | → 126 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/21/2018 | 569.93% | 摩根大通 | → 115 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for AnaptysBio (ANAB)?
AnaptysBio（ANAB）的目標價格是多少？
The latest price target for AnaptysBio (NASDAQ: ANAB) was reported by Wedbush on November 3, 2023. The analyst firm set a price target for $20.00 expecting ANAB to rise to within 12 months (a possible 16.51% upside). 10 analyst firms have reported ratings in the last year.
Wedbush於2023年11月3日公佈了AnaptysBio（納斯達克股票代碼：ANAB）的最新目標股價。該分析公司將目標股價設定爲20.00美元，預計ANAB將在12個月內上漲至20.00美元（可能上漲16.51％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for AnaptysBio (ANAB)?
AnaptysBio（ANAB）的最新分析師評級是多少？
The latest analyst rating for AnaptysBio (NASDAQ: ANAB) was provided by Wedbush, and AnaptysBio maintained their neutral rating.
AnaptysBio（納斯達克股票代碼：ANAB）的最新分析師評級由Wedbush提供，AnaptysBio維持中性評級。
When is the next analyst rating going to be posted or updated for AnaptysBio (ANAB)?
AnaptysBio（ANAB）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與AnaptysBio的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。AnaptysBio的最後一次評級是在2023年11月3日提交的，因此你應該預計下一個評級將在2024年11月3日左右公佈。
Is the Analyst Rating AnaptysBio (ANAB) correct?
分析師評級AnaptysBio（ANAB）是否正確？
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a maintained with a price target of $18.00 to $20.00. The current price AnaptysBio (ANAB) is trading at is $17.17, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但AnaptysBio（ANAB）的最新評級維持不變，目標股價爲18.00美元至20.00美元。AnaptysBio（ANAB）目前的交易價格爲17.17美元，超出了分析師的預測區間。